SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

SELLAS Life Sciences Group Inc.

The latest update is out from SELLAS Life Sciences Group ( ($SLS) ). On June 16, 2026, SELLAS Life Sciences Group, Inc. held its Annual Meeting of ...

SELLAS Stockholders Approve Governance and Equity Plan Changes

Analysts have been eager to weigh in on the Materials sector with new ratings on Wheaton Precious Metals (WPM), Ramelius Resources Limited (RMLRF) ...

Analysts Offer Insights on Materials Companies: Wheaton Precious Metals (WPM), Ramelius Resources Limited (OtherRMLRF) and Solaris Resources (SLSR)

The latest announcement is out from SELLAS Life Sciences Group ( ($SLS) ). SELLAS Life Sciences Group, Inc. reported that as of March 31, 2026, it ...

SELLAS Life Sciences boosts liquidity through warrant exercises

Global Surfaces Limited ( ($IN:GSLSU) ) has issued an announcement. Global Surfaces Limited’s board has approved the audited standalone and consoli...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	SLS	$8.05	+3.74%	14.75M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	SLS	$8.05	+3.7%	14.75M
3
4
5
6

SLS

SLS

Recent News for SLS

Get SELLAS Life Sciences Group Inc. Data in Excel

Get SELLAS Life Sciences Group Inc. Data in Excel